IPM valued at Rs 9,032 crores in Feb 2017

Domestic companies continued to dominate the market with a 78 per cent share in MAT February 2017 with a growth of 10 per cent

The Indian Pharmaceutical Market (IPM) was valued at Rs 9,032 crores in the month of February 2017 reflecting a growth of 3 per cent. On a MAT February basis, the industry was valued at Rs 113,474 crores and reflected a growth of 9 per cent which was slightly lesser than 10 per cent growth of January 2017 MAT.

Top 150 Company Snapshot

• The top 150 companies continue to account for 97% of IPM on MAT and month basis
• For the month, Top 10 companies have reflected stronger performance over the next category of companies while the highest growth is in the companies ranked between 31-40

Retail sector was valued at Rs 7,603 crores with a growth of 3 per cent SPLY for the month of February 2017. The retail channel remained the largest channel in IPM contributing 84 per cent of the overall sales and reflected a 9 per cent growth on MAT Basis. The hospital and doctor channel contributed to 10 per cent and 6 per cent of the overall sales and reflected 8 per cent and 11 per cent growth respectively. It is expected that the hospital channel will continue to report robust growth rates due to rapid capacity expansion in this space. As per QuintilesIMS data which captures sales from trade stockists, more than 10 Therapy Areas in the IPM have already crossed a sale of Rs 500 crores in the hospital segment and reflect healthy growth. Vaccines reflected de-growth on account of supply issues with key players in the market.

Top 40 Brands

• Mixtard continues to be the top brand with a MS of ~0.5%
• Novomix and Janumet have grown by 52% and 74% in Feb 2017
• Other brands with remarkable growth are Spasmo Proxyvon +, Duphaston, Pan D and Gluconorm-G

IPM continued to remain fragmented with top 10 companies occupying 43 per cent share. While top 10 companies grew at 10 per cent collectively, 11-20 companies reflected subdued growth at
8 per cent over previous year for the month of February 2017. Among the top 10 companies, five companies showed a double digit growth: Sun Pharma and Mankind Pharma grew at 11 per cent, Alkem grew at 12 per cent while Lupin and Macleods both grew at 13 per cent each. Glenmark grew fastest among the 11-20 companies at 15 per cent followed by Aristo at 14 per cent.

Domestic companies continued to dominate the market with a 78 per cent share in MAT February 2017 with a growth of 10 per cent. MNCs on the other hand reflected a growth of 7 per cent for the MAT. Large MNCs like Abbott, GSK and Pfizer which contributed around 57 per cent of the total MNC share in the MAT reflected growths of 9 per cent, 4 per cent and 1 per cent respectively. GSK’s new launch Enteroplus (LACTOBACILLUS RHAMNOSUS) clocked a value of Rs 90 lakhs in two months of launch.

Acute therapy remained the strongest pillar of IPM with a 64 per cent contribution to the total market which reduced from 67 per cent in the month of October 2016. Acute therapy continued to reflect a slowdown with a 1.2 per cent growth for the month of February 2017. Chronic therapy area on the other hand outpaced acute therapy reflecting a growth of 6.4 per cent for the month.

Cardiac continued to be the largest therapy area for the month, clocking a revenue of Rs 1088 crores. Amlodipine + Telmisartan (14 per cent), Telmisartan + HCT (11 per cent), Olmesartan (9 per cent) were among the fastest growing cardiac molecules for the month while Atorvastatin (-19 per cent), Amlodipine (-17 per cent) and Telmisartan (-12 per cent) were among the top molecules which reflected de-growth.

Anti-infectives retained its number two slot for the month with a value of Rs 1070 crores. Seven out of top 10 molecules reflected de-growth for the month. Amoxyclav solids (-4 per cent), Ceftrixone injection (-20 per cent), Cefixime solids (-14 per cent) and Azithromycin solids (-10 per cent) were among the top molecules reflecting de-growth.

Acute and Chronic Therapy Trends

Gastrointestinals continued to be the third largest therapy area for the month garnering a revenue of Rs 953 crores with a 4 per cent growth over SPLY. Dicyclomine combinations reflected a 35 per cent growth for the month. Pantoprazole + Domperidone and Rabeprazole + Domperidone continue to be the largest molecules in the segment reflecting a 15 per cent and 9 per cent growth respectively.

Anti-diabetics maintained its fourth position in IPM for the month of February 2017 clocking a growth of 15 per cent over SPLY. DPP4 inhibitors were the largest drug category in the anti-diabetic space with Teneligliptin contributing 21 per cent of the category by value. Seven out of top 10 molecules showed an impressive double digit growth, four out of them reflected a growth above 20 per cent: Glim + Met + Vogli combination (33 per cent), DPP4 inhibitors (28 per cent), Glime + Met (24 per cent) and SGLT2 inhibitors (138 per cent). Jardiance and Forxiga drove the spectacular growth of SGLT2 (138 per cent), each grew individually at 225 per cent and 52 per cent respectively for the month.

Dermatology, one of the fastest growing therapy areas in IPM registered the growth of 15 per cent SPLY for the month, with a value of Rs 652 crores. Anti-fungals and Itraconazole (107 per cent) reflected highest growth among top categories with emollients continuing to dominate the therapy area with a value of Rs 77 crores for the month.

Neurology reflected a 4 per cent growth for the month over SPLY, Levetiracetam continued to be the largest molecule in the space clocking a value of Rs 42 crores with a 12 per cent growth for the month. Oxcarbazepine reflected a healthy 17 per cent growth with a value of Rs 17 crores for the month.

Global (January 2017)

The global pharma market is valued at $1051 billion growing at 3.8 per cent. The US continues to dominate the market with 42 per cent market share with growth of 4.5 per cent.

Amongst the top market, India has moved a position up and is ranked seventh in the month of January 2017. Only market which has shown value growth more than 5 per cent in the month of January globally is China in the Top 15 markets. Critical observation to be made in the month of January is; US, Japan, Venezuela, Spain, Australia and Russia have shown more than 15 per cent de-growth.

Indian companies hold 1.5 per cent share in the global market and growing faster than the global market as per January 2017 data. For the month of January 2017, the IPM showed growth and all Top 10 companies showed growth.

(QuintilesIMS is a leading global information and technology services company providing end-to-end solutions to the life sciences and healthcare industry)